Mass General's Cancer Center is a global pioneer in personalized cancer therapy, which matches molecularly-targeted medications to the genetic anomalies that support the growth of cancer cells. Clinical trials can start at an earlier stage of the disease thanks to this genotype-based approach to medication development, offering patients more hope for better results.
The Termeer Center for Targeted Therapies is a leader in the creation of cancer treatments that are genetically targeted. The Termeer Center, housed in the Mass General Cancer Center, is a group of very gifted researchers and medical professionals who care for patients there and participate in 29 treatment programs.
The facility tests novel, experimental medications that target molecules involved in cancer growth, progression, and spread. These medications might be immunotherapies, chemotherapies, or targeted medicines targeting genes linked to a given cancer type.
The Termeer Center conducts research to select individuals for clinical trials and find malignancies that are genetically responsive to molecularly targeted therapy. This genotype-based strategy is far quicker than conventional clinical trials and enables researchers to evaluate these medications across many cancer types.
The former CEO of the biotechnology business Genzyme Corporation, Henri Termeer, donated $10 million to help establish the institute. He intends to match the gift with an extra $10 million from Boston-area benefactors.
The Center for Molecular Therapeutics combines laboratory-based scientists with medical professionals undertaking interventional therapy trials at the Karmanos Cancer Institute to find novel molecules, targets, or approaches that enhance cancer therapies. Structure-based biology, drug discovery and development, pharmacology, pharmacogenomics, and oncogenic signaling are the main topics of study in the Molecular Therapeutics program.
To find innovative drugs, antibodies, and small molecule delivery systems that may be useful to doctors in their quest to enhance patient lives, the Molecular Therapeutics group employs structural biology, machine learning, computational approaches, and biophysics. To comprehend protein structure better, molecular therapy researchers also use X-ray crystallography, NMR, and other cutting-edge methods.
The Molecular Therapeutics program of the Indiana Clinical and Translational Sciences Institute serves as a clearinghouse for resources for drug development, including compound library sharing and collaborative translational research partnerships. It also supports investigations on toxicity related to absorption, distribution, metabolism, and excretion to ease the transition from drug discovery to commercialization.
The hub connecting and coordinating findings in the fundamental sciences with translational research and clinical trials is the Center for Experimental Therapeutics (ET). Accelerating the translation of laboratory findings into efficient treatments is intended to enhance patient outcomes.
Leading authorities in biomedical imaging, genetics, and proteomics are also members of the ET team. Together, these researchers are creating novel cancer therapeutics that build on fresh molecular targets and improve on currently used regimens like chemotherapy and surgery.
Members of the Center create novel methods to forecast the response of novel anticancer medications and their interaction with systemic treatment modalities to individualize care and improve results. These methods combine analyses of tissue, blood, and imaging biomarkers.
A nationwide network of academic institutions, pharmaceutical firms, and lone researchers called the ETCTN conducts early-stage experimental therapeutic clinical studies. The ETCTN, which includes more than 60 research teams and hundreds of scientists from the nation, is the biggest single-institutional cooperation of its type.
Pre- and post-doctoral trainees with a background in cellular and molecular biology are supported by the T32 Program. Participants obtain supervised research experience during their Program, along with didactic and seminar instruction.
This training scholarship offers a special chance to educate doctors and/or Ph.D. scientists to become independent researchers in transdisciplinary cancer prevention and control research. This multidisciplinary method of teaching researchers equips them with industry and academic medicine employment.
Each year, trainees may apply for up to six T32 training positions. For conferences, seminars, and other T32-related activities, they will be given financial assistance with stipends and travel expenses.